Get the Stockscreener App
3.64
1.96%
0.07
Adagene Inc Adr stock is traded at $3.64, with a volume of 18,081.
It is up +1.96% in the last 24 hours and up +4.00% over the past month.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
See More
Previous Close:
$3.57
Open:
$3.62
24h Volume:
18,081
Relative Volume:
0.08
Market Cap:
$240.50M
Revenue:
$7.69M
Net Income/Loss:
$-17.65M
P/E Ratio:
-9.7248
EPS:
-0.3743
Net Cash Flow:
$-15.72M
1W Performance:
+11.66%
1M Performance:
+4.00%
6M Performance:
+117.96%
1Y Performance:
+86.67%
1-Day Range:
$3.56
$3.6999
1-Week Range:
$3.163
$3.6999
52-Week Range:
$1.30
$4.75
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.64 | 240.50M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Guggenheim | Buy |
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Jan-31-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Adagene Inc Adr Stock (ADAG) Latest News
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineIchimoku Entry - newsline.com
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Presents Two Posters at AACR 2026 with New Data - GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
Analysts Offer Predictions for Adagene FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
Leerink raises Adagene stock price target to $8 on combination data - Investing.com India
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):